Isolation and antiproliferation of tumor cells by a novel peptide (TC22) from the beetle Tribolium castaneum

Anticancer peptides (ACPs) are biologically anticancer active molecules that are produced by mammals, plants, insects and microorganisms. Here, a new peptide (TC22) with the amino acid sequence MTVVLLLIVLPLLGGVHSSGIL was identified and characterized from the beetle Tribolium castaneum . We found it...

Full description

Saved in:
Bibliographic Details
Published in:Amino acids 2019-02, Vol.51 (2), p.311-318
Main Authors: Liu, Xiao-dong, Zhang, Fu-xin, Qin, Zhi-hua, Shan, Hu
Format: Article
Language:English
Subjects:
Amino acid sequence
Analytical Chemistry
Apoptosis
Biochemical Engineering
Biochemistry
Biomedical and Life Sciences
Cancer
Caspase
Caspase-3
Caspase-9
Flow cytometry
Insects
Life Sciences
Microorganisms
Mitochondria
Neurobiology
Original Article
p53 Protein
Peptides
Plants (botany)
Proteomics
Reagents
Transcription
Tribolium castaneum
Tumor cells
Viability
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticancer peptides (ACPs) are biologically anticancer active molecules that are produced by mammals, plants, insects and microorganisms. Here, a new peptide (TC22) with the amino acid sequence MTVVLLLIVLPLLGGVHSSGIL was identified and characterized from the beetle Tribolium castaneum . We found it inhibited the growth and viability of HeLa and MCF-7 cells. Flow cytometry analysis demonstrated the TC22 induced HeLa cell apoptosis, and activated caspase-9 and caspase-3. Furthermore, TC22 led to ROS generation, and triggered p53 transcription and expression. Taken together, our results indicated that TC22 exhibited high anticancer capacity via activating p53, inducing ROS generation and through a mitochondrial pathway. This research provided a novel natural source peptide with strong anticancer capacity. These findings provide some novel insights on the potential candidate reagent in cancer treatment.
ISSN:0939-4451
1438-2199
DOI:10.1007/s00726-018-2666-8